The growth of Viagra and its impact on the pharmaceutical landscape presents a intricate question for shareholders. While the first sales statistics were impressive, the exclusivity has ended, leading to a flood of off-brand alternatives that are eroding profit. Moreover, the industry is facing challenges related to aging trends and evolving health